NewTimeSpace (newtimespace.com) News, on September 3, 2026, the chip theme weakened amid volatility while ASMPT (00522.HK) strengthened against the trend. As of 13:46, the stock was quoted at HKD 161.600, up 2.67%.
NewTimeSpace (newtimespace.com) News, on September 3, 2026, the robot theme rose amid volatility while XIAOMI-W (01810.HK) weakened. As of 13:33, the stock was quoted at HKD 27.320, down 2.64%.
On 3 September 2026, HUTCHMED (00013.HK) announced that its subsidiary has entered into an exclusive licence agreement with GSK for the global rights (excluding Greater China) to HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted conjugate, involving an upfront payment of USD 110 million and milestone payments of up to USD 1.295 billion; HUTCHMED retains Greater China rights and will lead the global Phase I development, expected to commence in the second half of 2026.
CENTURY GP INTL (02113.HK) plans to issue in total 160.95 million shares by subscription, with estimated net proceeds of HKD 43.3 million.
On 3 September 2026, IMPACT THERAP-B (07630.HK) announced that executive director and CEO Dr. Cai Suixiong purchased 100,000 shares on the open market at an average price of approximately HKD 14.6105 per share (approximately 0.035% of the issued shares), raising his holding to 18,540,884 shares, approximately 6.564%; Dr. Cai did not rule out further increases.
On 2 September 2026, CH BIOTECH SER (08037.HK) announced that its Penbo (Hainan) BNCT Hospital has entered into a framework cooperation agreement with Oncare Cancer Centre of Hong Kong to establish cross-border oncology cooperation under an "overseas assessment, domestic treatment, overseas follow-up" model; the Hospital operates in the Boao Lecheng pilot zone, and the first 10 head and neck cancer patients achieved an overall response rate of 80%.
On 2 September 2026, HATCHER GROUP (08365.HK) provided an update on its low-altitude economy investment: Hong Kong Cross-border signed a strategic investment LOI with Pengcheng Linghang for Greater Bay Area cross-border drone logistics cooperation, under which Pengcheng Linghang committed to purchase 2,000 drones and lead financing of no less than RMB 2 billion; the Company's stake in Hong Kong Cross-border has been reduced from 51% to 15%, and the LOI is not legally binding.
On 3 September 2026, AKESO (09926.HK) announced that the OS interim analysis of the HARMONi-2 study of ivonescimab (PD-1/VEGF) as first-line treatment for PD-L1-positive NSCLC met the key secondary OS endpoint with statistical significance and clinical benefit; the study had previously met its primary PFS endpoint (median PFS 11.14 vs 5.82 months, HR=0.51).
On 3 September 2026, CHINAGOLDINTL (02099.HK) announced its inclusion in the Hang Seng Momentum Index and the Hang Seng HK Stock Connect SOE Quality Index, with the change to take effect after the market close on 4 September and from 7 September; the Company stated it will continue to advance key projects including the Jiama Mine expansion and underground mining construction at the Changshanhao Gold Mine.
On 3 September 2026, CUTIA-B (02487.HK) announced that the BLA for CU-20101 (botulinum toxin type A for injection) has been accepted by the NMPA for the indication of improving moderate to severe glabellar lines; the product's manufacturing process will not use animal-derived materials or human serum albumin, aiming to eliminate the risks of TSE infection and allergic reactions.
On 2 September 2026, LEADER EDU (01449.HK) announced that its controlling shareholder Shuren Education entered into a sale and purchase agreement with Scienjoy Innovation Labs Inc. to sell 239,234,000 shares (approximately 29.9%) for approximately HKD 102.69 million; upon completion, Shuren together with Junhua Education will still hold 32.18% and remain the controlling shareholders, and the sale is subject to conditions precedent and may or may not proceed.
On 2 September 2026, Hatcher Group Limited (HATCHER GROUP, 08365.HK) published a further voluntary announcement stating that Qianyi Intelligent Technology Co., Ltd. had bought back 36% of the company's interest in Hong Kong KuaJingTong Aviation Technology Co., Ltd. for HKD 1, reducing the group's stake from 51% to 15% upon completion; Hong Kong KuaJingTong has signed a strategic investment LOI with Shenzhen Pengcheng Linghang Low-altitude Industry Co., Ltd. to pursue a low-altitude economy cross-border logistics project, under which Pengcheng Linghang plans to transfer 10% of its equity, commit to purchasing 2,000 commercial drones and lead the introduction of no less than RMB 2 billion in funding. The LOI is not legally binding and the contemplated transactions may not proceed.
On 2 September 2026, China Health Group Inc. (C HEALTH GP, 08225.HK) announced, on a voluntary basis, an update on its receivables recovery: receivables with a carrying amount of RMB 128 million as of 31 December 2024 have been fully provided for; after its arbitration claims against a related party were dismissed in full, the company has applied to set aside the arbitration award and is following up on the court's review; newly collected amounts from customers with a positive repayment attitude totaled RMB 2.088 million since 3 June 2026; and the company has established a receivables management committee to strengthen collection and internal controls, with the final recovery outcome subject to uncertainty.
On 2 September 2026, Victory Giant Technology (HuiZhou) Co., Ltd. (VGT, 02476.HK) published an overseas regulatory announcement in which its A-share unit (300476) disclosed the progress of guarantees between its third-level wholly-owned subsidiaries: Hunan MFS Technology (PCB) Co., Ltd. and Hunan MFS Technology (Hunan) Co., Ltd. signed maximum guarantee agreements with China CITIC Bank Changsha Branch, providing mutual joint and several liability guarantees of RMB 30 million in aggregate; the amounts fall within the company's 2026 estimated guarantee quota of no more than RMB 2,634.45 million and require no further approval. The aggregate outstanding guarantee balance stood at RMB 2,244.3084 million as of the disclosure date, equivalent to 13.51% of audited net assets at end-2025, with no guarantees to entities outside the consolidation scope and no overdue guarantees.
On 2 September 2026, Keymed Biosciences Inc. (KEYMED BIO-B, 02162.HK) announced an exclusive license agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the registration and commercialization of its in-house developed IL-4Rα monoclonal antibody Stapokibart injection (Kangyueda) in 18 countries and regions — 11 in Southeast Asia, 5 in Central Asia, plus Hong Kong and Macao; Keymed will receive an upfront payment, milestone payments and high-double-digit royalties based on net sales, and will continue to handle manufacturing and supply.
On 2 September 2026, Viva Goods Company Limited (VIVA GOODS, 00933.HK) announced that its wholly-owned subsidiary had acquired a further 17,253,500 shares of Li Ning Company Limited (LI NING, 02331.HK) on the open market through the Stock Exchange, representing approximately 0.67% of Li Ning's issued share capital, for a total consideration of approximately HKD 228,207,000 at an average price of approximately HKD 13.23 per share; upon completion, Viva Goods' stake in Li Ning rose from approximately 16.91% to 17.58%, with Li Ning continuing to be accounted for as an associate.
